Best of ASH & SABCS 2024, Seattle
The Best of ASH & SABCS 2024, Seattle, is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders and breast cancer. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.
This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders and breast cancer with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients.
Target Audience
- Hematologists, Oncologists
- Surgeons
- Radiation Oncologists
- Physician Assistants/Nurse Practitioners
- Pharmacists
- Nurses
Organizing Committee
Course Director:
Binay Shah, MD, MHA - Binaytara Foundation
Co-Chairs:
Andrew J. Cowan, MD - Fred Hutchinson Cancer Center, University of Washington
Fengting Yan, MD, PhD, FACP - Swedish Cancer Institute
Organizing Commitee Members:
Loan Retchless, ARNP, MSN- Panacea Oncology
Venue Information
If you are attending this meeting and need to reserve a hotel room, please reserve your room at the link below to take advantage of the discounted group rate of $149 per night plus applicable taxes and fees:
https://www.hyatt.com/en-US/
The deadline to reserve the hotel room is Friday, December 15, 2023.
Learning Objectives
- Review data presented at the ASH2023 and SABCS2023 & discuss their applications in clinical settings.
- Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer, understanding appropriate indications and contraindications to these therapeutic approaches.
- Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology and breast cancer.
- Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.
- Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.
Global Oncology Project
To learn more about our ongoing project building a 200-bed cancer hospital in Nepal.
DAY 1 - January 5th, 2024
All times are listed in Pacific Time (PT)
04:00 PM – 04:45 PM: Registration/Networking & Exhibits
04:45 PM – 05:00 PM: Opening remarks
05:00 PM – 06:30 PM: Session 1 – Case-based discussion
Moderator: David Aboulafia, MD
Case 1 – Bleeding disorder- Livia Hegerova, MD
Case 2 – Smoldering myeloma- Aaron Goodman, MD
Case 3 – ITP/TTP- Sandhya Panch, MD, MPH
Case 4 – Anemia- Kleber Fertrin, MD, PhD
Case 5 – Bone marrow failure- Sioban Keel, MD
06:30 PM – 07:15 PM: Networking/reception & Exhibits
DAY 2 - January 6th, 2024
07:00 AM – 07:55 AM: Breakfast & Exhibits
08:00 AM – 09:30 AM: Session 2
Moderator: Rachel Salit, MD
08:00 AM – 08:25 AM: MDS/Acute Leukemia- Jacob Appelbaum, MD, PhD
08:25 AM – 08:50 AM: Myeloproliferative neoplasms and CML- Vivian Oehler, MD
08:50 AM – 09:15 AM: Cellular therapy in hematologic malignancies – recent updates- Krish Patel, MD
09:15 AM – 09:30 AM: Q & A
09:30 AM – 10:00 AM: Break & exhibits
Product Theater Sponsored by Novartis *Non CME Activity* in Discovery Room
Topic: Addressing the Needs of Patients Across the HR+/HER2- Landscape: The Role of KISQALI (Ribociclib)
Speaker: Karthik Kumaravel, Associate Director, Market Access Strategy – Breast and Women’s Cancer
10:00 AM – 11:45 AM: Session 3
Moderator: Andrew Cowan, MD
10:00 AM – 10:25 AM: Lymphoma- Mengyang Di, MD, PhD
10:25 AM – 10:50 AM: Chronic lymphocytic leukemia- Mazyar Shadman, MD, MPH
10:50 AM – 11:15 AM: Multiple myeloma- Rahul Banerjee, MD, FACP
11:15 AM – 11:45 AM: Q & A
11:45 AM - 12:45 PM: Lunch & exhibits
Product Theater Sponsored by AstraZeneca *Non CME Activity* in Discovery Room
Topic: TRUQAP + fulvestrant: A Novel 2L Treatment Option for HR+/HER2- aBC or mBC With PIK3CA/AKT1/PTEN Alterations
Speaker: Dr. Lee Schwartzberg
12:45 PM - 02:30 PM: Session 4
Moderator: Tanya Wahl, MD
12:45 PM - 01:10 PM: Hormone receptor positive breast cancer- Hannah Linden, MD, FACP
01:10 PM - 01:35 PM: HER2 positive breast cancer- William Gwin III, MD
01:35 PM - 02:00 PM: Triple negative and HER2 low breast cancer- Sara Hurvitz, MD, FACP
02:00 PM – 02:30 PM: Q & A
02:30 PM – 02:45 PM: Break & exhibits
02:45 PM – 04:30 PM: Session 5
Moderator: Jennifer Specht, MD
02:45 PM – 03:10 PM: Radiotherapy – best breast practice- Li-Ming Christine Fang, MD
03:10 PM – 03:35 PM: Updates in surgical approach – best breast practice- Meghan Flanagan, MD, MPH
03:35 PM – 03:45 PM: Q & A
03: 45 PM- 04:00 PM: Arthracycline debate: To give or not to give- Jennifer Specht, MD
04:00 PM – 04:30 PM: Case-based discussion
Case 1 – DCIS- Lynn Symonds, MD
Case 2 – Inflammatory breast cancer- Peter Jiang, MD, PhD
Case 3 – Early Stage breast cancer- Danielle File, MD
04:30 PM – 04:35 PM: Adjourn
If you are attending this meeting and need to reserve a hotel room, please reserve your room at the link below to take advantage of the discounted group rate of $149 per night plus applicable taxes and fees:
https://www.hyatt.com/en-US/
The deadline to reserve the hotel room is Friday, December 15, 2023.
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Binay Shah, MD, MHA
Andrew Cowan, MD
Fengting Yan, MD
Jacob Appelbaum, MD/PhD
Rahul Banerjee, MD, FACP
Mengyang Di, MD, PhD
L. Christine Fang, M.D.
Meghan Flanagan, MD, MPH, FACS
William Gwin
Sara Hurvitz, MD
Hannah Linden, MD FACP
Vivian Oehler
Krish Patel, MD
Mazyar Shadman, MD,MPH
Kleber Fertrin, MD, PhD
Danielle File, MD
Aaron Goodman, MD
Livia Hegerova
Peter Jiang
sioban keel, Siobán Keel, MD. Associate Professor of Medicine, University of Washington. Robert & Phyllis Henigson Endowed Chair, Medical Director of Fred Hutchinson Cancer Center Hematology Malignancy Genetics Clinic, Medical Director of The University of Washingto
Sandhya Panch, MD MPH
Jennifer Specht, MD
Lynn Symonds
David Aboulafia, MD
Andrew Cowan, MD
Rachel Salit, MD
Tanya Wahl, Medical Oncologist, Medical Director Providence Swedish Cancer Institute Issaquah
LOAN RETCHLESS
Available Credit
- 8.25 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 8.25 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 8.25 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.